Page Title
Drug Development Pipeline
ELX-02
Status
Phase TwoTherapeutic Approach
Restore CFTR Protein
ELX-02 is a compound designed to restore CFTR function in people with CF who have nonsense mutations. Nonsense mutations (also known as “x” or “stop” mutations) in the CFTR gene cause the production of CFTR protein to stop prematurely. ELX-02 is intended allow lung cells to override these premature stop signals and make full-length, functional CFTR protein.
Status
A Phase 2 study to test the safety and tolerability of ELX-02 was conducted. The study was for people with CF who have at least one copy of the G542X CFTR mutation.
Sponsor
This program is sponsored by Eloxx Pharmaceuticals and is being conducted within the Therapeutics Development Network.
Sign up for clinical trial alerts
Get email updates about clinical trials that matter to you.
Explore clinical trials
Be a part of the movement transforming the future of cystic fibrosis treatment.
Learn More